Cochrane · systematic review · CD002785
Chelation therapy for atherosclerotic cardiovascular disease
Villarruz-Sulit, MVanessa, Forster, R, Dans, AL, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 4 · 57.1%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
EDTA compared to placebo for atherosclerotic cardiovascular disease
Population: atherosclerotic cardiovascular disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality EDTA vs placebo | RR 0.97 [0.73, 1.28] | 2 studies · 1792 participants | Low Downgraded: imprecision |
Coronary heart disease death EDTA vs placebo | RR 1.02 [0.7, 1.48] | 1 study · 1708 participants | Very low Downgraded: imprecision, inconsistency |
Myocardial infarction EDTA vs placebo | RR 0.81 [0.57, 1.14] | 2 studies · 1792 participants | Moderate Downgraded: imprecision |
Angina EDTA vs placebo | RR 0.95 [0.55, 1.67] | 2 studies · 1792 participants | Very low Downgraded: imprecision, inconsistency |
Stroke EDTA vs placebo | RR 0.88 [0.4, 1.92] | 2 studies · 1867 participants | Low Downgraded: risk of bias, imprecision |
Ankle‐brachial pressure index at 3 months post‐treatment EDTA vs placebo | no estimate extracted | 2 studies · 181 participants | Low Downgraded: risk of bias, imprecision |
Maximum walking distance (m) at 3 months post‐treatment EDTA vs placebo | no estimate extracted | 2 studies · 165 participants | Low Downgraded: risk of bias, imprecision |